galleon pharmaceuticals

Galleon is focusing our efforts on well-defined markets associated with high morbidity and mortality. Our initial product development efforts are aimed towards treating / preventing respiratory depression in a post-surgical setting. Our oral products are focused on a subset of sleep apnea patients and at risk (for respiratory depression) chronic pain patients.

Management

  • James C. Mannion, Ph.D. President, CEO and Founder of Galleon

    Jim Mannion has a 25-year record of technical innovation and commercial success in the pharmaceutical industry that includes clinical development (Burroughs Wellcome, Beecham), drug safety (Beecham), regulatory affairs (SmithKline Beecham), business unit development and management (Quintiles), corporate venture capital (Quintiles) and biotechnology senior management (EpiGenesis, Aptus, and Galleon).

    Jim's scientific and business training includes pharmacy (B.S., Ohio Northern), pharmacy administration (M.S., Purdue), clinical pharmacy (Ph.D., Purdue), clinical drug research/drug development (Post-doctoral fellowship, University of North Carolina) and management (University of Tennessee). Purdue University named Jim a Distinguished Alumnus in 2002.

  • D. Euan MacIntyre, Ph.D. Senior Vice President, Drug Discovery

    Euan MacIntyre is a scientist and executive with 25 years of pharmaceutical industry experience. Prior to his appointment at Galleon, Euan spent 23 years at Merck where he was Vice President, Basic Research-Pharmacology, and 2 years at Arete Therapeutics where he was Senior Vice President and Head of Drug Discovery. Prior to joining Merck, he was a tenured faculty member in pharmacology at his alma mater, The University of Glasgow. He has significant expertise in the translational aspects of pre-clinical pharmacology and has provided leadership for drug-discovery programs across a range of therapeutic areas. Euan has been directly involved with advancing 40 compounds from discovery into preclinical and clinical development, including several marketed products. He is the author or co-author of more than 150 publications in the areas of pharmacology and its application to drug discovery.

    Euan received his Ph.D. in pharmacology and experimental pathology from Cambridge University and completed post-doctoral fellowships at Cambridge and Harvard Universities.

  • James F. McLeod, M.D. Senior Vice President, Clinical Research & Development and Chief Medical Officer

    James McLeod is a physician scientist and pharmaceutical executive with 18 years of experience spanning preclinical and all phases of clinical development. Prior to joining Galleon, he headed the Experimental Medicine group at Merck Research Laboratories and the Early Clinical Research and Experimental Medicine group at the Schering-Plough Research Institute (SPRI). He joined SPRI from Novartis in 2004, where he headed the Clinical Pharmacology, Experimental Clinical Pharmacology and Translational Medicine groups. He has extensive clinical development experience with individual or group leadership of 24 new drug approvals globally spanning all major therapeutic areas including 8 neuroscience and respiratory medications.

    James has degrees in biomedical and chemical engineering (Rensselaer Polytechnic Institute) and medicine (University of Connecticut) and is board-certified in internal medicine and endocrinology and metabolism. He has been a research fellow in endocrinology and metabolism and human genetics and held positions at the University of Pennsylvania and Northwestern University medical schools. He is a past chair of the PhRMA Clinical Pharmacology Technical Group.

  • Lynne M. Brookes Senior Vice President and Chief Business Officer

    Lynne Brookes is a marketing executive with nearly 25 years of experience in pharmaceutical sales, product management and business development. Prior to joining Galleon, she was Vice President of Business Development at Cephalon, Inc. where she evaluated opportunities across multiple therapeutic areas and conducted numerous business transactions. She joined Cephalon in 1995 as a product manager and was responsible for commercializing many of Cephalon's pharmaceutical products including PROVIGIL, the company's most successful drug. Previously, Lynne was a Senior Associate, Endocrine Products, at Genentech and a Sales Representative and Medicinal Chemist at Merck & Co.

    Lynne has a Bachelor's degree in chemistry from Yale University and a Master's degree in business administration from The Wharton School at the University of Pennsylvania where she concentrated in health care management and marketing.

  • Scott L. Dax, M.S., Ph.D. Chief Technology Officer and Vice President, Chemistry

    Scott Dax is a pharmaceutical researcher and executive with over 20 years of experience in the areas of anti-infectives, analgesics and ventilatory agents. Prior to joining Galleon, he held positions of increasing responsibility at Hoffmann-La Roche, the Dupont-Merck Pharmaceutical Company and Johnson & Johnson. In 2008, Scott joined Galleon and established the company's chemistry operations (medicinal, analytical, intellectual property).

    Scott has delivered 4 NCEs into clinical trials in the past 5 years and 11 compounds into early development during a 7-year tenure as J&J Research Team leader. Scott has published in the areas of beta-lactam and quinolone antibacterials, cannabinoids, neuropeptide Y and bradykinin inhibitors, delta and mu opioid agonists and TRP ion channel modulators. He has authored more than 40 publications, 40 abstracts, 3 book chapters, 18 issued US patents and more than 100 worldwide patent filings. Scott has been an adjunct professor at Neumann College and Montclair State College and received Masters and Doctorate degrees from The University of Michigan (J.P. Marino) and a National Institutes of Health Postdoctoral Fellowship (University of Wisconsin- E. Vedejs).

  • Sean Peng, Ph.D. Head, Bioanalysis and DMPK

    Sean Peng has over seventeen years of pharmaceutical research experience in the areas of analytical/bioanalytical chemistry, in vitro ADMET, in vivo PK/PD and formulation development. Prior to joining Galleon Pharmaceuticals, Sean headed bioanalysis/DMPK groups at Johnson & Johnson and Procter & Gamble, respectively.

    Sean obtained his Ph.D. from the University of Illinois at Urbana-Champaign. He has published more than forty peer-reviewed research articles, invited reviews and book chapters and received an AAPS award for his work on hyphenated separation technologies.

  • Francis J. Golder, B.V.Sc., Ph.D., DACVA Head, Biology

    Frank Golder is a veterinary anesthesiologist who has trained with some of the top breathing-control experts in the world. Prior to joining Galleon, Frank was a member of the faculty at the University of Pennsylvania School of Veterinary Medicine. His cutting-edge research focused on the plasticity of breathing control with specific emphasis on long term facilitation for respiratory motor function in animal models of spinal cord injury. Frank is leading Galleon's efforts in discovery biology, which include establishing in vivo models of sleep-disordered breathing and identifying novel therapeutics for control of breathing disorders.